Q-omics provides the consensus-scored ARRDC4 profile across patient tissues and cancer cell-line models. ARRDC4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, ARRDC4 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, ARRDC4 protein abundance shows 23,577 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LGG, HNSC, and LSCC as cancer lineages where ARRDC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARRDC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARRDC4 survival associations across molecular data types. ARRDC4 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARRDC4 RNA expression–survival associations across cancer types. High ARRDC4 expression shows unfavorable associations in LGG, LUAD, SKCM and HNSC, but favorable associations in DLBC and UCEC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for ARRDC4 RNA expression.
This table summarizes ARRDC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ARRDC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARRDC4 shows lower tumor expression in KICH, COAD, THCA, LUAD and LUSC and higher tumor expression in HNSC. The HNSC box plot shows higher ARRDC4 RNA expression in tumor versus normal tissue (log2 FC = +1.555, t-test p < 0.001).
This table shows molecular features associated with ARRDC4 in patient tissues and cancer cell lines. In patient samples, ARRDC4 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ARRDC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
